Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases

Zitta Barrella Harboe,1,2 Sebastian Rask Hamm,3 Laura Pérez-Alós,4 Pradeesh Sivapalan,5 Helene Priemé,5 Torgny Wicke,5 Peter Kjeldgaard,5 Saher Shaker,5 Alexander Svorre Jordan,5 Dina Leth Møller,3 Line Dam Heftdal,6,8 Johannes Roth Madsen,4 Rafael Bayarri-Olmos,4 Cecilie Bo Hansen,4 Mia Marie Pries-Heje,5 Rasmus Bo Hasselbalch,8 Kamille Fogh,6,8 Jose Juan Almagro Armenteros,8 Linda Hilsted,9,10 Erik Sørensen,10 Birgitte Lindegaard,1,2 Andrea Browatzki,1 Tor Biering-Sørensen,8 Ruth Frikke-Schmidt,2,10 Sisse Rye Ostrowski,2,11 Kasper Karmark Iversen,2,8,12 Henning Bundgaard,2,7 Susanne Dam Nielsen,2,3 Peter Garred,2,4 Jens-Ulrik Stæhr Jensen,2,5,13

ABSTRACT

Introduction Responses to COVID-19 vaccination in patients with chronic pulmonary diseases are poorly characterised. We aimed to describe humoral responses following two doses of BNT162b2 mRNA COVID-19 vaccine and identify risk factors for impaired responses.

Methods Prospective cohort study including adults with chronic pulmonary diseases and healthcare personnel as controls (1:1). Blood was sampled at inclusion, 3 weeks, 2 and 6 months after first vaccination. We reported antibody concentrations as geometric means with 95% CI of receptor binding domain (RBD)-IgG and neutralising antibody index of inhibition of ACE-2/RBD interaction (%). A low responder was defined as neutralising index in the lowest quartile (primary outcome) or RBD-IgG <225 AU/ml plus neutralising index <25% (secondary outcome), measured at 2 months. We tested associations using Poisson regression.

Results We included 593 patients and 593 controls, 75% of all had neutralising index >97% at 2 months. For the primary outcome, 34.7% of patients (n=157/453) and 12.9% of controls (n=46/359) were low responders (p<0.001). For the secondary outcome, 8.6% of patients (n=39/453) and 1.4% of controls (n=5/359) were low responders (p<0.001). Risk factors associated with low responder included increasing age (per decade, adjusted risk ratio (aRR) 1.17, 95%CI 1.03 to 1.32), Charlson Comorbidity Index (per point) (aRR 1.15, 95%CI 1.05 to 1.26), use of prednisolone (aRR 2.08, 95%CI 1.55 to 2.77) and other immunosuppressives (aRR 2.21, 95%CI 1.65 to 2.97).

Discussion Patients with chronic pulmonary diseases established functional humoral responses to vaccination, however lower than controls. Age, comorbidities and immunosuppression were associated with poor immunological responses.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Today, close to 545 million people live with chronic pulmonary diseases, making such diseases some of the leading causes of morbidity and mortality worldwide. Patients with chronic pulmonary diseases are among the most susceptible individuals to developing severe and critical COVID-19. Until now, responses to COVID-19 vaccination in patients with chronic pulmonary diseases are poorly characterised.

WHAT THIS STUDY ADDS

⇒ This is the first study that explores humoral responses following two doses of mRNA BNT162b2 COVID-19 vaccination for up to 6 months.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY

⇒ Most patients with chronic pulmonary diseases responded adequately to vaccination, however, humoral responses were lower compared with controls. Furthermore, we found that age, comorbidities and use of systemic corticosteroids and other immunosuppressants, were all independently associated with having a lower response to vaccination.

INTRODUCTION

Patients with chronic pulmonary diseases, including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), severe asthma and bronchiectasis, are at increased risk of severe and critical COVID-19.1–4 In addition, several retrospective cohort studies and case
series have reported an increased risk of hospitalisation, intensive care unit admission and mortality related to severe COVID-19 in patients with chronic pulmonary diseases, with risk estimates differing between disease groups. Thus, protective means, including vaccination of individuals with chronic pulmonary diseases, are crucial in preventing morbidity and mortality related to SARS-CoV-2 infection.

High vaccine effects after two doses of mRNA COVID-19 vaccination have been reported from both phase III randomised placebo controlled studies and large population observational studies. Over time, a gradual decline in vaccine efficacy has been described, raising concerns about the sustained long-term protection conferred by vaccination and the subsequent introduction of an additional third or fourth vaccine dose in several countries. Published studies indicate that vaccine efficacy estimates reported from non-immunocompromised patients with chronic diseases are similar between risk groups. However, the characteristics and dynamics of humoral responses after mRNA COVID-19 vaccination in patients with chronic pulmonary diseases remain to be described.

We aimed to describe humoral responses following two doses of BNT162b2 mRNA COVID-19 vaccination and identify risk factors for impaired immunological responses in patients with chronic pulmonary diseases since this is a large group of patients with increased risk for severe COVID-19.

PATIENTS AND METHODS
Setting and study design
We conducted a prospective cohort study. Patients attending an outpatient clinic at the Department of Pulmonary Medicine at Herlev, Gentofte or North Zealand University Hospitals in Copenhagen, Capital Region, Denmark, from 15 January 2021 to 31 May 2021, were invited to participate in the study. The BNT162b2 mRNA COVID-19 vaccine (Comirnaty, Pfizer-BioNTech) was administered free of charge and used as one of the COVID-19 vaccines recommended by the Danish Health Authority in the vaccination programme. Participation in the study did not alter the vaccination timing or schedule.

The design and report of the study were done following the Strengthening the Reporting of Observational Studies in Epidemiology statement.

Participants
Inclusion criteria
Patients aged 18 years and older, attending one of the outpatient’s clinics at one of the study sites due to any of the following diagnoses of chronic pulmonary diseases (all requiring respiratory medicine specialist treatment): COPD, α-1 antitrypsin deficiency, ILD (including idiopathic pulmonary fibrosis), sarcoidosis, severe asthma, bronchiectasis or sleep apnoea. Healthcare personnel aged 18 years and older, who have received the BNT162b2 mRNA COVID-19 vaccine were included as the control population, as previously described. Approximately 89.7% of the population has Danish origin.

Exclusion criteria
SARS-CoV-2 laboratory-confirmed infection determined by the presence of antibodies against the nucleocapsid protein (N-protein) before vaccination or during follow-up. To compare antibody responses between patients and controls, we matched by sex and the nearest age at the time of first vaccination (1:1).

Exposures, variables and outcomes
Exposure
BNT162b2 mRNA COVID-19 vaccine.

Variables
Age, sex, diagnosis of underlying chronic pulmonary disease, comorbidities (estimated by Charlson Comorbidity Index (CCI)), lung function expressed as the forced expired volume in the first second (FEV1), body mass index (BMI), immunosuppression (eg, use of oral steroids, another immunosuppressive drug (Anatomical Therapeutic Chemical codes L04), inhaled corticosteroids (ICS) and antifibrotic drugs. In addition, we categorised patients with the following diagnoses: (1) COPD, α-1 antitrypsin deficiency, asthma, bronchiectasis and sleep apnoea as obstructive lung diseases (OLD); (2) patients with diffuse parenchymal pulmonary disease and sarcoidosis as ILD.

Follow-up
Baseline (from inclusion and to up to 13 days after the first dose), at 3 weeks (from 14 days and up to 33 days after the first dose and before administration of a second dose), at 2 months (between 34 days and up to 90 days after the first dose and only after administration of a second dose); and at 6 months (from 91 days and up to 273 days after the first dose). These time points correspond to the median time of the obtained samples.

Outcomes
Defined as a responder or low responder after two BNT162b2 mRNA COVID-19 vaccine doses. In the absence of an internationally validated cut-off value for a serological correlate of protection, we defined arbitrary outcomes based on current data suggesting that postimmunisation antibody levels and neutralising activity can be used as a valid measure to estimate short-term protection. Therefore, we defined the primary outcome as the antibody neutralising activity alone, expressed as the percentage (%) of inhibition of ACE-2 host receptor and the spike-glycoprotein receptor-binding domain (RBD) of SARS-CoV-2 interaction. For the primary outcome, a low responder was defined as an individual having a neutralising antibody index in the lowest quartile of the study population measured at least 2 weeks after the second dose of BNT162b2 mRNA COVID-19 vaccine.
(categorised as ‘2 months sample’). As a secondary outcome, we defined low responder as a combined outcome based on (1) the detection of RBD IgG antibodies expressed as arbitrary unit per mL (AU/mL) <25 AU/mL, concomitantly with (2) the detection of neutralising antibodies index <25% measured at least 2 weeks after the second dose of BNT162b2 mRNA COVID-19 vaccine (categorised as ‘2 months sample’). Laboratory analyses were performed as previously described.20 25 26

Data sources and statistical methods
Baseline clinical information was retrieved from patients’ medical files and for healthcare personnel from questionnaires fulfilled by study subjects at study entry. We matched patients and controls by the nearest age at the time of first vaccination in a 1:1 ratio using nearest neighbour matching with the Optmatch package in R.27 28 Continuous data were reported as medians with IQR, and differences were assessed by Mann-Whitney U test or t-test, as most appropriate. Categorical data were reported as frequency counts and percentages, and differences were evaluated using the $\chi^2$ test or Fisher’s exact test, as most appropriate. Missing data were handled by using complete-case analysis.

Sample size
We estimated that we needed to include 500 patients with chronic pulmonary diseases to detect a clinically significant risk increase for being a low responder (primary outcome) of at least an OR of 1.4 or more, using a significant risk increase for being a low responder (primary outcome). For the immunological assays, we reported RBD IgG antibody levels as geometric mean concentrations (GMC) and neutralising antibodies were reported as the neutralising index (%) of inhibition of ACE-2 with 95% CI, and neutralising antibodies were reported as frequency counts and percentages, and differences were evaluated using the $\chi^2$ test or Fisher’s exact test, as most appropriate. Missing data were handled by using complete-case analysis.

Patient and public involvement
Patients were not involved in developing the research question and outcome measures, design, recruitment and conduction of the study. The laboratory analysis results have been made available to study participants through electronic patient records.

RESULTS
Baseline characteristics
We included 626 patients diagnosed with chronic pulmonary disease who received a BNT162b2 mRNA COVID-19 vaccine, 33 patients were excluded since they only received one dose of vaccine, 593 were included in the further analysis. Baseline characteristics of patients and controls are shown in table 1. Compared with controls, patients with chronic pulmonary diseases were older, were more often males and had higher BMIs. The interval between the first and second vaccine dose was shorter for patients than for controls. Among patients, 67% (n=398/593) had OLD, 30% (n=183/593) had ILD, 8% (n=50/593) had both, 27% (n=160/593) had moderate to high levels of comorbidities (CCI ≥2). At the time of vaccination, 13% (n=76/593) were on systemic oral steroids (excluding those given during acute exacerbation), 11% (n=64/593) were on other immunosuppressive drugs, 7.4% (n=44/593) on anti-fibrotic agents, 29% (n=170/593) on ICS, 5% (n=30/593) were active smokers, 51% (n=305/593) were previous smokers.

Primary and secondary humoral outcomes in patients and controls
Humoral responses for the primary and secondary outcomes at different sampling time points during follow-up are shown in table 2. After two doses of the BNT162b2 mRNA COVID-19 vaccine, the three upper

| Table 1  | Baseline characteristics of patients with chronic pulmonary diseases and controls included in the study |
|----------|------------------------------------------------------------------------------------------------------|
|          | Patients | Controls | P value       |
| N        | 593      | 593      | <0.001        |
| Median age, years (IQR) | 68 (58–74) | 62 (57–64) | <0.001        |
| Male gender, n (%) | 283 (47.7) | 193 (32.5) | <0.001        |
| Median time between first and second vaccine dose, days, (IQR) | 23 (22–25) | 30 (29–32) | <0.001        |
| BMI, mean (SD) | 27.2 (6.4) | 25.4 (6.4) | <0.001        |
| BMI, body mass index. |
Changes in the antibody concentrations and neutralising antibody index with 95% CI of the mean at different sampling time points during follow-up are shown in figures 1 and 2. Antibody concentrations in patients and controls increased significantly from baseline to 3 weeks after the first dose and at 2 months sample (figure 1). There was a decline in measured antibody concentrations from 2 to 6 months after the first vaccine dose in both patients and controls (figure 2).

Humoral responses are expressed as the proportion of responders and low responders in each group. For the primary outcome, a low responder was defined as an individual having a neutralising antibody index measured in the lower quartiles of the total study population had a detectable neutralising index of 97%. For the primary outcome, 34.7% patients (n=157/453) and 12.9% of controls (n=46/359) were low responders (p<0.0001). For the secondary outcome, 8.6% patients (n=39/453) and 1.4% of controls (n=5/359) were low responders (p<0.0001). At 2 and 6 months of follow-up, a significantly higher proportion of patients with chronic pulmonary diseases were low responders following two doses of the BNT162b2 mRNA COVID-19 vaccine than controls for both the primary and secondary outcomes (table 2). For the secondary outcome, the differences in humoral responses were also significant after the first dose of the vaccine (table 2).

Table 2  Humoral responses to the BNT162b2 mRNA COVID-19 vaccine in patients with chronic pulmonary disease and controls according to the primary and secondary immunological outcomes at different times during follow-up

| Time of sampling | Patients (N, %) | Controls (N, %) | Difference (%) | P value |
|------------------|----------------|----------------|---------------|---------|
|                  | Responder | Low responder | Responder | Low responder |               |               |
| Baseline         | 0 (0)     | 566 (100)     | 0 (0)      | 581 (100)     | 0            | –             |
| 3 weeks          | 4 (0.88)  | 447 (99.1)    | 2 (0.43)   | 455 (99.6)    | 0.45         | 0.67          |
| 2 months         | 296 (65.3)| 157 (34.7)    | 313 (67.1) | 46 (12.9)     | 21.8         | <0.0001       |
| 6 months         | 44 (38.9) | 69 (61.1)     | 243 (63.9) | 137 (37.1)    | 25           | <0.0001       |

Risk factors associated with a lower response to vaccination in patients with chronic pulmonary diseases

Risk ratio (RR) from the univariate and multivariate analysis, including factors of clinical importance associated with being a low responder in patients with chronic pulmonary disease at 2 months of follow-up are shown in table 3. Increasing age per 10 years (crude RR (cRR) 1.19, 95% CI 1.05 to 1.35; adjusted RR (aRR) 1.17, 95% CI 1.03 to 1.32), an increase in CCI (cRR 1.20, 95% CI 1.10 to 1.31; aRR 1.15, 95% CI 1.05 to 1.26), use of prednisolone (cRR 2.12, 95% CI 1.59 to 2.81; aRR 2.08, 95% CI 1.55 to 2.77) and use of other immunosuppressive drugs (cRR 2.04, 95% CI 1.52 to 2.72; aRR 2.21, 95% CI 1.65 to 2.97) were significantly associated with an increased risk for being a low responder.

Antibody profiles in patients and controls

Changes in the antibody concentrations and neutralising antibody index with 95% CI of the mean at different sampling time points during follow-up are shown in figures 1 and 2. Antibody concentrations in patients and controls increased significantly from baseline to 3 weeks after the first dose and at 2 months sample (figure 1). There was a decline in measured antibody concentrations from 2 to 6 months after the first vaccine dose in both patients and controls (figure 2).

DISCUSSION

In this prospective cohort study, including patients with chronic pulmonary diseases who were vaccinated with two doses of the BNT162b2 mRNA COVID-19 vaccine, we found that most patients could establish functional humoral responses to vaccination characterised by high antibody titres and high levels of neutralising antibodies. However, humoral responses were lower at 2 and 6 months in patients with chronic pulmonary diseases than those observed in controls, and varied at different
sampling points. We also identified risk factors of clinical importance for an impaired response to vaccination in patients with chronic pulmonary diseases, including increasing age, having more underlying comorbidities and using oral steroids or other immunosuppressive drugs. However, these results must be interpreted with caution in the absence of correlates of protection against severe outcomes when we report our results.

In patients with chronic pulmonary diseases and controls, we observed high antibody titres and neutralising antibody index when the peak of immunity after the mRNA BNT162b2 vaccine would be expected.29 30 An explanation for the use of two different immunological outcomes for assessing the results of humoral responses in our study is that at the time we designed the study, conducted and reported the analysis, there was no...
international consensus on the definition of correlates of protection after COVID-19 vaccination, either on the seropositivity threshold or the level of neutralising antibodies. Therefore, we considered it reasonable to define our primary outcome based on the measurement of neutralising index alone as an indicator of functional mediation of protection. We determined this threshold as the neutralising antibody level measured in the lower quartile of the study population. This showed to be a conservative assumption since several groups have reported a neutralising index >50% or median neutralising antibody titres (NT50) as thresholds.29 31 32 Thus, other thresholds for protection will lead to different estimates of humoral responses.

A recently published analysis of the immune correlate of mRNA-1273 COVID-19 vaccine from the efficacy trial indicated that vaccine efficacy increases with higher antibody titres and is highly mediated by neutralising antibodies.33 Based on this consideration, we defined a secondary outcome as a composite outcome that combined antibody titres and neutralising antibodies.25 26 In both cases, by using any of the defined immunological outcomes, we found that humoral responses were consistently lower in patients with chronic pulmonary diseases, especially in asthma patients,34 35 that antifibrotic drugs of inhalation corticosteroids, and immunosuppression, including corticosteroids, has markedly reduced humoral and cellular immunogenicity of mRNA COVID-19 vaccines compared with healthy controls.31 36 37 We did not find evidence to support that antifibrotic drugs of inhalation corticosteroids were associated with poorer immunological outcomes after vaccination. Interestingly, similar findings have been reported from patients with autoimmune diseases with lung involvement, which are more likely to receive immunosuppression.36 Current guidelines for vaccination of immunocompromised patients recommend that vaccines should be administered before planned immunosuppression if feasible.38 Such considerations should be based on the risk of severe COVID-19 infection with and without immunological responses and the risk of pausing immunosuppression.

Some potential limitations to our study deserve careful consideration. First, we do not have information on the cause of the lost to follow-up of some patients. Most severely ill patients have been prioritised for COVID-19 vaccine effectiveness might also be reduced against current and forthcoming SARS-CoV-2 variants of concern.19 Our results support that waning humoral immunity also occurs in individuals with chronic pulmonary diseases, similar to what we observed in the control population. While there have been conflicting reports on the risk of SARS-CoV-2 infection in patients with chronic pulmonary diseases, especially in asthma patients,34 35 their increased risk of severe outcomes after infection is well established.1–4 Several industrialised countries have introduced additional third and fourth doses to their COVID-19 vaccination schedules in light of the waning immunity after vaccination, which is highly relevant for patients with chronic pulmonary diseases.35

The identified risk factors for being a low responder have not been extensively characterised for other groups than severely immunocompromised patients. Iatrogenic immunosuppression, including corticosteroids, has been reported from patients with autoimmune diseases with lung involvement, which are more likely to receive immunosuppression.36 Current guidelines for vaccination of immunocompromised patients recommend that vaccines should be administered before planned immunosuppression if feasible.38 Such considerations should be based on the risk of severe COVID-19 infection with and without immunological responses and the risk of pausing immunosuppression.

Some potential limitations to our study deserve careful consideration. First, we do not have information on the cause of the lost to follow-up of some patients. Most severely ill patients have been prioritised for COVID-19 vaccinations over time, with the subsequent risk of breakthrough infections.29 34
vaccination during the study period, leading to a selection bias of included patients and probably explaining at least in part the proportion of lost to follow-up in the cohort. Patients with incomplete data were similar to those with complete follow-up regarding baseline characteristics, besides a slightly higher proportion of males (data not shown) might affect the immunogenicity results. Second, although we matched patients and controls by sex and the nearest age, we could not match for age per-year increase, and healthcare personnel were younger and more often females. We conducted the analysis without matching, with similar results irrespective of whether matching or not was applied, but we cannot rule residual confounding completely out. Third, medical information from the controls was incomplete. Fourth, the duration of follow-up was not sufficient to assess waning long-term immunogenicity. Furthermore, even if we did not find a statistically significant difference between the time interval between the first and second doses, the time between the two doses was numerically slightly shorter for patients than for controls. However, the optimal time interval has been identified as 8 weeks, and since we observed only a few days shorter interval in the patients than in the controls, we do not suspect this could alter significantly the signal of our results. Finally, we did not have immunological markers of cellular immunity, which are also related to immunological protection after vaccination.

CONCLUSIONS

Most patients with chronic lung diseases could establish functional humoral responses to vaccination, but humoral responses were lower at 2 and 6 months in patients with chronic pulmonary diseases than those observed in controls. Age, comorbidities and the use of different immunosuppressants were all associated with impaired immunological responses.
REFERENCES

1 Lacedonia D, Sciocchia G, Santomassi C, et al. Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients. Sci Rep 2021;11:19231.

2 Hadby VB, Lakhani DA, Naqvi SFZ, et al. Outcomes of SARS-CoV-2 infection in patients with pulmonary sarcoïdosis: a multicenter retrospective research network study. Respir Med 2021;187:106538.

3 Aveyard P, Gao M, Lindson N, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med 2021;9:909–23.

4 Naqvi SF, Lakhani DA, Sohal AH, et al. Patients with idiopathic pulmonary fibrosis have poor clinical outcomes with COVID-19 disease: a propensity matched multicentre research network analysis. BMJ Open Respir Res 2021;8:e000969.

5 Reyes FM, Hache-Marliere M, Karamanis D, et al. Assessment of the association between COPD and asthma with in-hospital mortality in patients with COVID-19: a systematic review, meta-analysis, and meta-regression analysis. J Clin Med 2021;10:2087.

6 Beltramo G, Cottenet J, Mariet A-S, et al. Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study. Eur Respir J 2021;58:2004474.

7 Gerayeli FV, Milne S, Cheung C, et al. Copd and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine 2021;33:100789.

8 Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021;398:2093–100.

9 Dagan N, Barda N, Kepton E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412–23.

10 Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–16.

11 Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15.

12 Tartof SY, Sleazak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021;398:1407–16.

13 Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 2021;385:1761–73.

14 Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently Approved or authorized in the United States. Available: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html [Accessed 09 Dec 2021].

15 European Medicines Agency. Comirnaty and Spikevax: EMA recommendations on extra doses and boosters. Available: https://www.ema.europa.eu/en/news/comirnaty-spikevax-ema-recommendations-extra-doses-boosters [Accessed 09 Dec 2021].

16 Moline HL, Whitaker M, Deng L, et al. Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged ≥65 Years - COVID-NET, 13 states, February-April 2021. MMWR Mortal Wkly Rep 2021;70:1088–93.

17 Yelin I, Katz R, Herzeli E. Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities. medRxiv 2021:21253686.

18 Danish Health Authority. Vaccination against COVID-19. Available: https://www.dst.dk/en/english/corona-eng/vaccination-against-covid-19 [Accessed 09 Dec 2021].

19 Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of omicron in South Africa. Science 2022;376:eabm4947.

20 Hansen GB, Jarheit I, Hasselbalch RB, et al. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming. J Intern Med 2021;290:1272–4.

21 Statistics Denmark. Population projections. Available: https://www.dst.dk/en/Statistik/emner/borgere/befolning/befolkningsfremskrivning

22 Goldblatt D, Fiore-Gartland I, Johnson M, et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine 2022;40:306–15.

23 Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021;385:1474–84.

24 Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205–11.

25 Bayrami-Olmos R, Ikonen M, Rostenberg A, et al. SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain. J Immunol 2021;207:878–87.

26 Hansen GB, Jarheit I, Pérez-Alos L, et al. SARS-CoV-2 antibody responses are correlated to disease severity in COVID-19 convalescent individuals. J Immunol 2021;206:3722–31.

27 Johannesen CK, Rezahosseini O, Gylbe-Brask M, et al. Risk factors for being seronegative following SARS-CoV-2 infection in a large cohort of health care workers in Denmark. Microbiol Spectr 2021;9.e609024.

28 Iversen K, Bundgaard H, Hasselbalch RB, et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. Lancet Infect Dis 2020;20:1401–8.

29 Collier A-R, Yu J, McMahan K, et al. Differential kinetics of immune responses elicited by Covid-19 vaccines. N Engl J Med 2021;385:2010–2.

30 Falsey AR, Frenck RW, Walsh EE, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med 2021;385:1627–9.

31 Collier A-R, Yu J, McMahan K. COVID-19 mRNA vaccine immunogenicity in Immunosuppressed individuals. J Infect Dis. 2021;204:S99–104.

32 Payne RP, Longst S, Austin JA, et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 2021;184:5699–714.

33 Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022;375:43–50.

34 Goldberg Y, Mandel M, Bar-On Y. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med 2021.

35 Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC who clinical characterisation protocol UK. Lancet Respir Med 2021;9:699–711.

36 Ferri C, Ursini F, Alós L, et al. Differential kinetics of immune responses elicited by Covid-19 vaccines. J Epidemiol. 2021;52:279–81.

37 Buttiron Webber T, Provinciali N, Musso M, et al. Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in autoimmune systemic diseases. high prevalence of non-response in different patients’ subgroups. J Autoimmun 2021;125:102744.

38 Faresjo T, Faresjo A. To match or not to match in epidemiological studies—same outcome but less power. Int J Environ Res Public Health 2010;7:325–32.

39 Grunau B, Goldfarb DM, Asamoah-Boaheng M, et al. Immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals. JAMA 2022;327:279–81.

40 Skowronska DM, Febranin Y, Ouakki M, et al. Two-Dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. Clin Infect Dis.